Compounds > papaverine

papaverine and roflumilast

papaverine has been researched along with roflumilast in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
de Esch, IJ; de Graaf, C; Jansen, C; Kanev, GK; Kooistra, AJ; Leurs, R1
Bai, L; Gong, J; Jin, Y; Peng, T; Shi, J; Tong, R; Wei, X; Zhou, Y1
Bankala, R; Doss, HM; Kapavarapu, RK; Kulkarni, P; Kumar, JS; Mathew, JE; Medishetti, R; Mudgal, J; Pal, M; Parsa, KVL; Ramarao, EVVS; Rasool, M; Shenoy, GG; Sunke, R; Thirupataiah, B1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Bass, CR; Meaney, DF; Morales, FN; Morrison, B; Vogel, EW1
Ansari, MN; Rehman, NU; Samad, A1

Reviews

1 review(s) available for papaverine and roflumilast

ArticleYear
Inhibitors of phosphodiesterase as cancer therapeutics.
    European journal of medicinal chemistry, 2018, Apr-25, Volume: 150

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neoplasms; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship

2018

Other Studies

5 other study(ies) available for papaverine and roflumilast

ArticleYear
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
    Journal of medicinal chemistry, 2016, Aug-11, Volume: 59, Issue:15

    Topics: Databases, Protein; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship

2016
InCl
    European journal of medicinal chemistry, 2019, Jul-15, Volume: 174

    Topics: Animals; Arthritis; Cyclic Nucleotide Phosphodiesterases, Type 4; Encephalomyelitis, Autoimmune, Experimental; Freund's Adjuvant; Indium; Indoles; Molecular Structure; Multiple Sclerosis; Oligodendrocyte-Myelin Glycoprotein; Phosphodiesterase 4 Inhibitors; Quinoxalines; Rats; Structure-Activity Relationship; Zebrafish; Zebrafish Proteins

2019
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Phosphodiesterase-4 inhibition restored hippocampal long term potentiation after primary blast.
    Experimental neurology, 2017, Volume: 293

    Topics: Aminopyridines; Animals; Animals, Newborn; Benzamides; Blast Injuries; Cell Death; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Disease Models, Animal; Disks Large Homolog 4 Protein; Gene Expression Regulation; Glycine; Guanylate Kinases; Hippocampus; In Vitro Techniques; Long-Term Potentiation; Membrane Proteins; Papaverine; Phosphodiesterase 4 Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors

2017
In Silico, Ex Vivo and In Vivo Studies of Roflumilast as a Potential Antidiarrheal and Antispasmodic agent: Inhibition of the PDE-4 Enzyme and Voltage-gated Ca++ ion Channels.
    Molecules (Basel, Switzerland), 2020, Feb-24, Volume: 25, Issue:4

    Topics: Aminopyridines; Animals; Antidiarrheals; Benzamides; Binding Sites; Calcium Channel Blockers; Carbachol; Castor Oil; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Diarrhea; Isoproterenol; Jejunum; Mice; Molecular Docking Simulation; Papaverine; Parasympatholytics; Phosphodiesterase 4 Inhibitors; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Rabbits; Verapamil

2020